Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
June 20, 2005
- Non-consolidated Sales of 28 Listed JPMA Companies Up 0.8% to \4,184,156 Mil.
June 20, 2005
- 20% of Hepatitis C Patients Untreated Despite Diagnosis
June 20, 2005
- AstraZeneca, Shionogi Conducting Crestor PMS According to ICH E2E
June 20, 2005
- Kirin Establishes Local Subsidiary in Thailand
June 20, 2005
- France Invites Investments
June 20, 2005
- BUSINESS NEWS IN BRIEF
June 20, 2005
- NEW PRODUCTS
June 20, 2005
- Draft Basic Policy 2005 for Reform Announced
June 20, 2005
- LDP to Compile Priority Issues for Gov't Basic Policy 2005
June 20, 2005
- MOF Council Recommends "Urgent Measures" to Control Healthcare Benefits
June 20, 2005
- FPMAJ Members Exchange Views on Soseki Required by New PAL
June 20, 2005
- DPC Classification for 3 Treatments to Be Reviewed
June 20, 2005
- Market for Ethical Drugs Grew 3.5% to \7,345,657 Mil. in FY2004: IMS Japan
June 13, 2005
- LDP to Call For Enhancement of Int'l Competitiveness of Pharma Industry
June 13, 2005
- Novartis to Acquire Hexal AG
June 13, 2005
- Committee Recommends Import Approval for Kissei's Salagen
June 13, 2005
- Pfizer Qualitatively and Quantitatively Beefs Up Its Marketing
June 13, 2005
- Council Listens to Industry's Views on How to Strengthen Domestic Industry's Int'l Competitiveness
June 13, 2005
- FY2005 to Be "Milepost" for Teijin Pharm: Mr Ohyagi
June 13, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…